Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Executive Summary
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.
You may also be interested in...
Executives On The Move: AVEO Pharmaceuticals, Everest Medicines and More
Recent executive changes in the industry include C-suite changes at Aveo Pharmaceuticals and Scandion Oncology. Meanwhile, new directors were appointed at Akston Biosciences and Everest Medicines.
Pipeline Watch: 10 Approvals And Nine Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Beijing Konruns Pharmaceutical, KemPharm and More
Recent executive changes in the industry include C-suite changes at KemPharma and Imago BioSciences. Meanwhile, new directors were appointed at Beijing Konruns Pharmaceutical and Ventyx Biosciences.